IP Library Granted Patent US 9,750,688
Granted Patent B2
US 9,750,688 · App. 15/066,748 · Granted Sep 5, 2017

Glucan gels

Inventors: Rolf Engstad (Tromsø, NO); Stein-Tore Solem (Tromsø, NO); Dag-Eirik Ramsøy (Tromsø, NO)
Assignee: BIOTEC PHARMACON ASA
A61K9/06A61K9/0014A61K31/716A61L15/00A61L26/0023C08B37/0024C08J3/075C08J2305/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,688
App. No.
15/066,748
Granted
Sep 5, 2017
Kind
B2
Abstract

The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 5 g/mol and existing in gel form in aqueous solution at a concentration ≧1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.

Claims (13)

1. A method of assisting wound or ulcer healing or treating oral mucositis or cancer in a subject in need thereof which comprises administering to said subject a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 5 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C.

2. The method of claim 1 , wherein the glucan has a weight average molar mass of 20,000 to 40,000 g/mol on a single chain basis.

3. The method of claim 1 , wherein the gel glucan product has a melting temperature (gel to sol) of about 40° C.

4. The method of claim 1 , wherein the glucan is in aqueous solution at a concentration of 2% to 4%.

5. The method of claim 1 , wherein the glucan is in aqueous solution at a concentration of about 2%.

6. The method of claim 1 , wherein the glucan is derived from Saccharomyces cerevisiae.

7. The method of claim 1 , wherein the glucan is a beta glucan comprising a backbone of β-(1,3)-linked glucosyl residues and side chains comprising 2 or more β-(1,3)-linked glucosyl residues, the sidechains being attached to the backbone via a β-(1,6)-linkage.

8. The method of claim 1 , wherein the glucan is essentially free of repetitive β-(1,6)-linked glucosyl residues.

9. The method of claim 1 , wherein said ulcer is a diabetic ulcer.

10. The method of claim 1 , wherein the glucan is topically applied to a subject.

11. A physical support having applied thereto or impregnated therein, a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 5 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C.

12. The physical support of claim 11 selected from the group consisting of a woven, non-woven, knitted, foam or adhesive substrate; a patch, dressing, plaster, bandage, film or gauze.

13. An in vitro method of proliferation of skin cells which comprises contacting a population of skin cells with a gel glucan product comprising a soluble yeast glucan in aqueous solution at a concentration of 1 to 6%, the glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 5 g/mol, the gel glucan product having a gel to sol melting temperature of 35 to 60° C.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: BIOTEC BETAGLUCANS AS
To: DANSTAR FERMENT AG
Reel/Frame 065568/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2021
From: ARCTICZYMES TECHNOLOGIES ASA
To: BIOTEC BETAGLUCANS AS
Reel/Frame 055277/0220 →
CHANGE OF NAME Recorded Jan 5, 2021
From: BIOTEC PHARMACON ASA
To: ARCTICZYMES TECHNOLOGIES ASA
Reel/Frame 054900/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: ENGSTAD, ROLF; RAMSØY, DAK-EIRIK
To: BIOTEC PHARMACON ASA
Reel/Frame 048777/0849 →
Priority Claims (1)
GB 1020191.1 · Nov 29, 2010 · national
Continuity (2)
Division 13989594
Related Publication 20160256385A1 · Sep 8, 2016